Logo image of THAR

THARIMMUNE INC (THAR) Stock Price, Quote, News and Overview

NASDAQ:THAR - Nasdaq - US4327053090 - Common Stock - Currency: USD

1.54  -0.11 (-6.67%)

After market: 1.52 -0.02 (-1.3%)

THAR Quote, Performance and Key Statistics

THARIMMUNE INC

NASDAQ:THAR (5/7/2025, 8:00:02 PM)

After market: 1.52 -0.02 (-1.3%)

1.54

-0.11 (-6.67%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.39
52 Week Low0.95
Market Cap3.25M
Shares2.11M
Float2.08M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO01-12 2022-01-12


THAR short term performance overview.The bars show the price performance of THAR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

THAR long term performance overview.The bars show the price performance of THAR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of THAR is 1.54 USD. In the past month the price increased by 42.59%. In the past year, price decreased by -72.7%.

THARIMMUNE INC / THAR Daily stock chart

THAR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.31 332.73B
AMGN AMGEN INC 13.29 148.31B
GILD GILEAD SCIENCES INC 12.78 123.13B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.78B
REGN REGENERON PHARMACEUTICALS 12.66 60.56B
ARGX ARGENX SE - ADR 327.86 38.04B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.97B
ONC BEIGENE LTD-ADR N/A 25.03B
BNTX BIONTECH SE-ADR N/A 22.31B
NTRA NATERA INC N/A 21.77B
SMMT SUMMIT THERAPEUTICS INC N/A 18.04B
BIIB BIOGEN INC 7.41 17.17B

About THAR

Company Profile

THAR logo image Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

Company Info

THARIMMUNE INC

1200 Route 22 East

Bridgewater NEW JERSEY US

Employees: 3

THAR Company Website

THAR Investor Relations

Phone: 13027432995

THARIMMUNE INC / THAR FAQ

What is the stock price of THARIMMUNE INC today?

The current stock price of THAR is 1.54 USD. The price decreased by -6.67% in the last trading session.


What is the ticker symbol for THARIMMUNE INC stock?

The exchange symbol of THARIMMUNE INC is THAR and it is listed on the Nasdaq exchange.


On which exchange is THAR stock listed?

THAR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for THARIMMUNE INC stock?

7 analysts have analysed THAR and the average price target is 5.1 USD. This implies a price increase of 231.17% is expected in the next year compared to the current price of 1.54. Check the THARIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is THARIMMUNE INC worth?

THARIMMUNE INC (THAR) has a market capitalization of 3.25M USD. This makes THAR a Nano Cap stock.


How many employees does THARIMMUNE INC have?

THARIMMUNE INC (THAR) currently has 3 employees.


What are the support and resistance levels for THARIMMUNE INC (THAR) stock?

THARIMMUNE INC (THAR) has a resistance level at 1.55. Check the full technical report for a detailed analysis of THAR support and resistance levels.


Should I buy THARIMMUNE INC (THAR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does THARIMMUNE INC (THAR) stock pay dividends?

THAR does not pay a dividend.


What is the Price/Earnings (PE) ratio of THARIMMUNE INC (THAR)?

THARIMMUNE INC (THAR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.89).


What is the Short Interest ratio of THARIMMUNE INC (THAR) stock?

The outstanding short interest for THARIMMUNE INC (THAR) is 3.54% of its float. Check the ownership tab for more information on the THAR short interest.


THAR Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to THAR. When comparing the yearly performance of all stocks, THAR is a bad performer in the overall market: 92.53% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

THAR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to THAR. THAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

THAR Financial Highlights

Over the last trailing twelve months THAR reported a non-GAAP Earnings per Share(EPS) of -9.89. The EPS increased by 94.96% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -327.75%
ROE -932.83%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%80%
Sales Q2Q%N/A
EPS 1Y (TTM)94.96%
Revenue 1Y (TTM)N/A

THAR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to THAR. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners8.07%
Ins Owners1.48%
Short Float %3.54%
Short Ratio0.56
Analysts
Analysts82.86
Price Target5.1 (231.17%)
EPS Next Y5.23%
Revenue Next YearN/A